Radioimmunotherapy with alpha-emitting nuclides

被引：325

作者：

McDevitt, MR ^{[1
]}

Sgouros, G ^{[1
]}

Finn, RD ^{[1
]}

Humm, JL ^{[1
]}

Jurcic, JG ^{[1
]}

Larson, SM ^{[1
]}

Scheinberg, DA ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1998年 / 25卷 / 09期

关键词：

high linear energy transfer; bismuth-213; astatine-211; bismuth-212; actinium-225; alpha particle-emitting radionuclides;

D O I：

10.1007/s002590050306

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

This review discusses the application of alpha particle-emitting radionuclides in targeted radioimmunotherapy. It will outline the production and chemistry of astatine-211 bismuth-212, lead-212, actinium-225, bismuth-213, fermium-255, radium-223 and terbium-149, which at present are the most promising alpha-emitting isotopes available for human clinical use. The selective cytotoxicity offered by alpha particle-emitting radioimmunoconstructs is due to the high linear energy transfer and short particle path length of these radionuclides. Based upon the pharmacokinetics of alpha particle-emitting radioimmunoconstructs, both stochastic and conventional dosimetric methodology is discussed, as is the preclinical and initial clinical use of these radionuclides conjugated to monoclonal antibodies for the treatment of human neoplasia.

引用

页码：1341 / 1351

页数：11

共 67 条

[1] Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: The potential role of terbium-149 [J].